Thalidomide-O-amido-PEG2-C2-NH2 (TFA)

Background Introduction

Thalidomide-O-amido-PEG2-C2-NH2 (TFA) is a specialized E3 ligase ligand-linker conjugate designed for use in PROTAC (Proteolysis Targeting Chimera) technology. As a thalidomide derivative, it effectively recruits the cereblon E3 ubiquitin ligase complex. The addition of a PEG2-C2-amido linker and an amine (NH2) functional group facilitates flexible and straightforward coupling with various target ligands, making it an ideal building block for custom PROTAC synthesis.

Mechanism

Thalidomide-O-amido-PEG2-C2-NH2 (TFA) works by leveraging the thalidomide moiety to bind to the cereblon (CRBN) E3 ubiquitin ligase. The conjugate’s PEG2-C2-amido linker provides optimal spatial orientation and solubility, connecting the E3 ligase ligand to another small molecule ligand that targets a specific protein of interest. This bifunctional PROTAC molecule brings the E3 ligase and the target protein into close proximity, promoting ubiquitination and subsequent proteasomal degradation of the target protein. This mechanism offers potent, selective protein knockdown with advantages over traditional inhibition techniques.

Applications

Thalidomide-O-amido-PEG2-C2-NH2 (TFA) is widely used in the design and synthesis of custom PROTACs for targeted protein degradation research. It serves as an essential intermediate for conjugating cereblon-binding ligands to target protein ligands in innovative drug development, including cancer, neurodegenerative, and autoimmune disease models. Researchers use this conjugate to streamline PROTAC development workflows, enabling rapid evaluation of new protein targets, precise mechanism-of-action studies, and high-throughput screening campaigns for next-generation therapeutics.

Thalidomide-O-amido-PEG2-C2-NH2 (TFA) serves as a versatile E3 Ligase Ligand-Linker Conjugate in the development of PROTACs, facilitating targeted protein degradation by linking E3 ligases to target proteins. The following provides a detailed description of this molecule, including its linker, ligand, and selection of target protein ligands.

Linker: The linker in this molecule is characterized by a PEG2 chain that provides moderate flexibility, enhancing solubility and bioavailability. Its length is optimal for ensuring efficient proximity between the E3 ligase and the target protein. This linker is non-cleavable, which is ideal for stable conjugate formation.

Ligand: The ligand component is based on Thalidomide, a well-known E3 ligase recruiter. Its structural characteristics include a glutarimide moiety that effectively binds to cereblon, facilitating the recruitment of the E3 ubiquitin ligase complex for targeted protein degradation.

Reactive Site: The reactive site in this molecule is the terminal amine group, which couples with the target protein ligand via amide bond formation. Recommended reaction types include nucleophilic substitution or amidation reactions, ensuring robust and stable conjugate formation.

Recommended Target Protein Ligand: A compatible warhead for this molecule would be a small molecule inhibitor or binder with an exposed carboxylic acid or activated ester group. This provides the advantage of forming a stable amide linkage, which is crucial for effective target protein degradation. Such applications are pivotal in studying protein function and validating therapeutic targets in preclinical research.